Dr. David Standaert
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Washington University School of Medicine (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 144
Licensed in Alabama since 2006, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: Washington University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
AL license 27659 (first issued 2006; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Alabama Hospital Birmingham, AL
Medical groups
- University of Alabama Health Services Foundation, PC (2,814 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 144
- Services billed
- 329
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 73 | 72 |
| New patient office or other outpatient visit, 60-74 minutes | 35 | 35 |
| Established patient office or other outpatient visit, 40-54 minutes | 24 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Clonazepam Other prescribers in Birmingham, AL | 48 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Birmingham, AL | 25 |
| Nuplazid (pimavanserin tartrate) | 23 |
| Gabapentin Other prescribers in Birmingham, AL | 18 |
| Amantadine (amantadine hcl) Other prescribers in Birmingham, AL | 13 |
| Carbidopa-Levodopa-Entacapone (carbidopa/levodopa/entacapone) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 13 payments worth $17,141 in total to this clinician.
| Eli Lilly and Company | $8,725 |
|---|---|
| AbbVie Inc. | $5,333 |
| Biogen, Inc. | $3,083 |
| Consulting Fee | $15,420 |
|---|---|
| Travel and Lodging | $1,591 |
| Food and Beverage | $130 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company Nov 12, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $8,338 |
| Biogen, Inc. Dec 1, 2025 | Consulting Fee | $3,083 |
| AbbVie Inc. May 1, 2025 | Travel and Lodging travel to BROOKLYN, NY · in-kind | $842 |
| AbbVie Inc. Apr 11, 2025 | Consulting Fee | $800 |
| AbbVie Inc. Aug 5, 2025 | Consulting Fee | $800 |
| AbbVie Inc. Aug 5, 2025 | Consulting Fee VYALEV · NEUROSCIENCE | $800 |
| AbbVie Inc. Oct 15, 2025 | Consulting Fee VYALEV · NEUROSCIENCE | $800 |
| AbbVie Inc. Oct 15, 2025 | Consulting Fee | $800 |
| Eli Lilly and Company Nov 7, 2025 | Travel and Lodging travel to NEW YORK, AL · in-kind | $388 |
| AbbVie Inc. May 6, 2025 | Travel and Lodging travel to BROOKLYN, NY · in-kind | $361 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $53,888 in research payments for these studies, mostly to the institutions running them.
- Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
AbbVie Inc. · Active, not recruiting · NCT06107426 - Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease
AbbVie Inc. - Ph2a of IZD334 in Parkinsons disease
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.